Desmopressin (DDAVP) treatment in adult sleep-related enuresis

Gregory Katz; Baruch Spivak; Roberto Mester; Alex Grinshpoon; Abraham Weizman

doi:10.1002/(SICI)1099-1077(199709/10)12:5<505::AID-HUP916>3.0.CO;2-A

Desmopressin (DDAVP) treatment in adult sleep-related enuresis

Gregory Katz, Baruch Spivak, Roberto Mester, Alex Grinshpoon, Abraham Weizman

Research output: Contribution to journal › Article › peer-review

Abstract

In an open prospective study we investigated the efficacy of intranasal administration of 1-desamino-8-D-arginine vasopressin (DDAVP) in enuretic adults during military service. Twelve male enuretic soldiers aged 18-19 years (18.9 ± 0.5 years), with a history of resistance to tricyclic antidepressant treatment and to behavioural therapy, were included in the study. Patients were treated with 20-40 mg (bedtime dose) DDAVP. A significant decrease in the frequency of enuresis was demonstrated (3.4 ± 4.3 versus baseline of 8.2 ± 3.3 days, p = 0.01). Four patients achieved complete dryness and four patients achieved partial response. It seems that intranasal DDAVP can be an effective and safe treatment in young adult sleep-related enuresis.

Original language	English
Pages (from-to)	505-507
Number of pages	3
Journal	Human Psychopharmacology
Volume	12
Issue number	5
DOIs	https://doi.org/10.1002/(SICI)1099-1077(199709/10)12:5<505::AID-HUP916>3.0.CO;2-A
State	Published - 1 Sep 1997
Externally published	Yes

Keywords

1-desamino-8-D-arginine vasopressin (DDAVP desmopressin)
Sleep-related enuresis
Tricyclic antidepressants

ASJC Scopus subject areas

Neurology
Clinical Neurology
Psychiatry and Mental health
Pharmacology (medical)

Access to Document

10.1002/(SICI)1099-1077(199709/10)12:5<505::AID-HUP916>3.0.CO;2-A

Cite this

@article{76665704f575472fbf79a369271273ec,

title = "Desmopressin (DDAVP) treatment in adult sleep-related enuresis",

abstract = "In an open prospective study we investigated the efficacy of intranasal administration of 1-desamino-8-D-arginine vasopressin (DDAVP) in enuretic adults during military service. Twelve male enuretic soldiers aged 18-19 years (18.9 ± 0.5 years), with a history of resistance to tricyclic antidepressant treatment and to behavioural therapy, were included in the study. Patients were treated with 20-40 mg (bedtime dose) DDAVP. A significant decrease in the frequency of enuresis was demonstrated (3.4 ± 4.3 versus baseline of 8.2 ± 3.3 days, p = 0.01). Four patients achieved complete dryness and four patients achieved partial response. It seems that intranasal DDAVP can be an effective and safe treatment in young adult sleep-related enuresis.",

keywords = "1-desamino-8-D-arginine vasopressin (DDAVP desmopressin), Sleep-related enuresis, Tricyclic antidepressants",

author = "Gregory Katz and Baruch Spivak and Roberto Mester and Alex Grinshpoon and Abraham Weizman",

year = "1997",

month = sep,

day = "1",

doi = "10.1002/(SICI)1099-1077(199709/10)12:5<505::AID-HUP916>3.0.CO;2-A",

language = "English",

volume = "12",

pages = "505--507",

journal = "Human Psychopharmacology",

issn = "0885-6222",

publisher = "John Wiley and Sons Ltd",

number = "5",

}

TY - JOUR

T1 - Desmopressin (DDAVP) treatment in adult sleep-related enuresis

AU - Katz, Gregory

AU - Spivak, Baruch

AU - Mester, Roberto

AU - Grinshpoon, Alex

AU - Weizman, Abraham

PY - 1997/9/1

Y1 - 1997/9/1

N2 - In an open prospective study we investigated the efficacy of intranasal administration of 1-desamino-8-D-arginine vasopressin (DDAVP) in enuretic adults during military service. Twelve male enuretic soldiers aged 18-19 years (18.9 ± 0.5 years), with a history of resistance to tricyclic antidepressant treatment and to behavioural therapy, were included in the study. Patients were treated with 20-40 mg (bedtime dose) DDAVP. A significant decrease in the frequency of enuresis was demonstrated (3.4 ± 4.3 versus baseline of 8.2 ± 3.3 days, p = 0.01). Four patients achieved complete dryness and four patients achieved partial response. It seems that intranasal DDAVP can be an effective and safe treatment in young adult sleep-related enuresis.

AB - In an open prospective study we investigated the efficacy of intranasal administration of 1-desamino-8-D-arginine vasopressin (DDAVP) in enuretic adults during military service. Twelve male enuretic soldiers aged 18-19 years (18.9 ± 0.5 years), with a history of resistance to tricyclic antidepressant treatment and to behavioural therapy, were included in the study. Patients were treated with 20-40 mg (bedtime dose) DDAVP. A significant decrease in the frequency of enuresis was demonstrated (3.4 ± 4.3 versus baseline of 8.2 ± 3.3 days, p = 0.01). Four patients achieved complete dryness and four patients achieved partial response. It seems that intranasal DDAVP can be an effective and safe treatment in young adult sleep-related enuresis.

KW - 1-desamino-8-D-arginine vasopressin (DDAVP desmopressin)

KW - Sleep-related enuresis

KW - Tricyclic antidepressants

UR - https://www.scopus.com/pages/publications/0030831893

U2 - 10.1002/(SICI)1099-1077(199709/10)12:5<505::AID-HUP916>3.0.CO;2-A

DO - 10.1002/(SICI)1099-1077(199709/10)12:5<505::AID-HUP916>3.0.CO;2-A

M3 - Article

AN - SCOPUS:0030831893

SN - 0885-6222

VL - 12

SP - 505

EP - 507

JO - Human Psychopharmacology

JF - Human Psychopharmacology

IS - 5

ER -

Desmopressin (DDAVP) treatment in adult sleep-related enuresis

Abstract

Keywords

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this